GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Agenus Inc (NAS:AGEN) » Definitions » 3-Year FCF Growth Rate

Agenus (Agenus) 3-Year FCF Growth Rate : 7.50% (As of Dec. 2023)


View and export this data going back to 2000. Start your Free Trial

What is Agenus 3-Year FCF Growth Rate?

Agenus's Free Cash Flow per Share for the three months ended in Dec. 2023 was $-2.12.

During the past 3 years, the average Free Cash Flow per Share Growth Rate was 7.50% per year. During the past 5 years, the average Free Cash Flow per Share Growth Rate was 1.50% per year. During the past 10 years, the average Free Cash Flow per Share Growth Rate was 6.40% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Free Cash Flow per Share growth rate.

During the past 13 years, the highest 3-Year average Free Cash Flow per Share Growth Rate of Agenus was 56.00% per year. The lowest was -67.40% per year. And the median was 6.65% per year.


Competitive Comparison of Agenus's 3-Year FCF Growth Rate

For the Biotechnology subindustry, Agenus's 3-Year FCF Growth Rate, along with its competitors' market caps and 3-Year FCF Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Agenus's 3-Year FCF Growth Rate Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Agenus's 3-Year FCF Growth Rate distribution charts can be found below:

* The bar in red indicates where Agenus's 3-Year FCF Growth Rate falls into.



Agenus 3-Year FCF Growth Rate Calculation

This is the 3-year average growth rate of Free Cash Flow per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Free Cash Flow per Share growth rate.


Agenus  (NAS:AGEN) 3-Year FCF Growth Rate Explanation

Free Cash Flow per Share is the amount of Free Cash Flow per outstanding share of the company's stock. Free Cash Flow is considered one of the most important parameters to measure a company's earnings power by value investors because it is not subject to estimates of Depreciation, Depletion and Amortization (DDA). However, when we look at the Free Cash Flow, we should look from a long term perspective, because any year's Free Cash Flow can be drastically affected by the spending on Property, Plant, & Equipment (PPE) of the business in that year. Over the long term, Free Cash Flow should give pretty good picture on the real earnings power of the company. It's used in the calculation of Forward Rate of Return (Yacktman) %.


Agenus 3-Year FCF Growth Rate Related Terms

Thank you for viewing the detailed overview of Agenus's 3-Year FCF Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.


Agenus (Agenus) Business Description

Traded in Other Exchanges
Address
3 Forbes Road, Lexington, MA, USA, 02421
Agenus Inc is an American clinical-stage company with a pipeline of therapies designed to activate the body's immune system to fight cancer and infections, including immune-modulatory antibodies, adoptive cell therapies through its subsidiary MiNK Therapeutics Inc. and vaccine adjuvants through its subsidiary SaponiQx Inc. This robust product pipeline is supported by company's in-house capabilities, including current good manufacturing practice (cGMP) manufacturing and a clinical operations platform. The company's antibody candidates are botensilimab (a proprietary next-generation Fc-engineered CTLA-4 antibody, also known as AGEN1811) and balstilimab (a PD-1 antibody).
Executives
Ulf Wiinberg director
Steven J O'day officer: Chief Medical Officer 2344 BANYAN DRIVE, LOS ANGELES CA 90049
Garo H Armen officer: Chairman & CEO 3 FORBES ROAD, LEXINGTON MA 02421
Christine M Klaskin officer: VP Finance 3 FORBES ROAD, LEXINGTON MA 02421
Adam Krauss officer: Chief Legal Officer 139 GRANIT STREET, MEDFIELD MA 02052
Susan B Hirsch director 280 OLD SOMERSET ROAD, WATCHUNG NJ 07069
Paul N Clark director 5301 STEVENS CREEK BLVD, MS 1A-LC, SANTA CLARA CA 95051
Incyte Corp 10 percent owner 1801 AUGUSTINE CUT-OFF, WILMINGTON DE 19803
Alex Duncan officer: Chief Technology Officer 3 FORBES ROAC, LEXINGTON MA 02421
Christian Cortis officer: See Remarks 3 FORBES ROAD, LEXINGTON MA 02421
Evan Kearns officer: V.P. and General Counsel AGENUS INC., 3 FORBES ROAK, LEXINGTON MA 02421
Jennifer Buell officer: Chief Operating Officer 3 FORBES ROAD, LEXINGTON MA 02421
Allison M Jeynes-ellis director FLAT 52, WILLIAM HUNT MANSIONS, LONDON X0 SW13 8HT
Wadih Jordan director ANTIGENICS INC., 162 FIFTH AVE., SUITE 900, NEW YORK NY 10010
Brian Corvese director C/O ANTIGENICS INC., 162 FIFTH AVENUE, SUITE 900, NEW YORK NY 10010